Beamr video compression achieves up to 50% improvement for AVs
Takeda Pharmaceutical (TADAWUL:2070) Company Limited (NYSE:TAK) has announced the convocation of its 149th Ordinary General Meeting of Shareholders, set to take place in Tokyo, Japan. The notice, filed with the U.S. Securities and Exchange Commission today, indicates the meeting is scheduled for May 2025.
In compliance with SEC regulations, the Japanese pharmaceutical giant disclosed the upcoming event in a Form 6-K filing, a requirement for foreign private issuers to provide information that may be of significance to shareholders. The document specifies that Takeda will continue to submit annual reports under Form 20-F, which is used by foreign private issuers to provide a comprehensive overview of the company’s financial health and operations for U.S. investors.
The notice of the shareholder meeting is listed as Exhibit 99.1 in the SEC filing, underscoring the importance of the event in the company’s governance calendar. The precise agenda for the meeting has not been detailed in the filing, but such gatherings typically cover the approval of financial statements, dividend distributions, and the election of board members, among other corporate governance matters.
Takeda Pharmaceutical, categorized under the Pharmaceutical Preparations industry (SIC code 2834), has its principal executive offices located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan. The company is well-known for its commitment to addressing complex health challenges and bringing transformative treatments to patients worldwide.
The Form 6-K filing was signed by Norimasa Takeda, the company’s Chief Accounting Officer and Corporate Controller, indicating that the necessary corporate authorization has been obtained for the report’s submission.
Investors and stakeholders of Takeda Pharmaceutical can refer to the SEC filing for further details regarding the upcoming shareholders meeting. The filing serves as an official communication to the market, ensuring transparency and compliance with international regulatory standards.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.